PMC:7243768 / 6623-6908 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"221","span":{"begin":98,"end":101},"obj":"Gene"},{"id":"222","span":{"begin":108,"end":112},"obj":"Gene"},{"id":"223","span":{"begin":194,"end":223},"obj":"Gene"},{"id":"224","span":{"begin":225,"end":228},"obj":"Gene"},{"id":"229","span":{"begin":56,"end":67},"obj":"Chemical"},{"id":"230","span":{"begin":147,"end":159},"obj":"Disease"}],"attributes":[{"id":"A221","pred":"tao:has_database_id","subj":"221","obj":"Gene:1636"},{"id":"A222","pred":"tao:has_database_id","subj":"222","obj":"Gene:185"},{"id":"A223","pred":"tao:has_database_id","subj":"223","obj":"Gene:1636"},{"id":"A224","pred":"tao:has_database_id","subj":"224","obj":"Gene:1636"},{"id":"A229","pred":"tao:has_database_id","subj":"229","obj":"MESH:D000450"},{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"MESH:D006973"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T55","span":{"begin":113,"end":117},"obj":"Body_part"}],"attributes":[{"id":"A55","pred":"fma_id","subj":"T55","obj":"http://purl.org/sig/ont/fma/fma12520"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T75","span":{"begin":147,"end":159},"obj":"Disease"}],"attributes":[{"id":"A75","pred":"mondo_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/MONDO_0005044"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T105","span":{"begin":20,"end":30},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T46","span":{"begin":44,"end":55},"obj":"Chemical"},{"id":"T47","span":{"begin":56,"end":67},"obj":"Chemical"},{"id":"T48","span":{"begin":194,"end":205},"obj":"Chemical"},{"id":"T49","span":{"begin":230,"end":240},"obj":"Chemical"},{"id":"T50","span":{"begin":245,"end":259},"obj":"Chemical"},{"id":"T53","span":{"begin":245,"end":256},"obj":"Chemical"},{"id":"T54","span":{"begin":257,"end":259},"obj":"Chemical"}],"attributes":[{"id":"A46","pred":"chebi_id","subj":"T46","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A47","pred":"chebi_id","subj":"T47","obj":"http://purl.obolibrary.org/obo/CHEBI_27584"},{"id":"A48","pred":"chebi_id","subj":"T48","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A49","pred":"chebi_id","subj":"T49","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"},{"id":"A50","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_2719"},{"id":"A51","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_48432"},{"id":"A52","pred":"chebi_id","subj":"T50","obj":"http://purl.obolibrary.org/obo/CHEBI_58506"},{"id":"A53","pred":"chebi_id","subj":"T53","obj":"http://purl.obolibrary.org/obo/CHEBI_48433"},{"id":"A54","pred":"chebi_id","subj":"T54","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T9","span":{"begin":129,"end":145},"obj":"http://purl.obolibrary.org/obo/GO_0042310"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T46","span":{"begin":0,"end":285},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T33","span":{"begin":147,"end":159},"obj":"Phenotype"}],"attributes":[{"id":"A33","pred":"hp_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/HP_0000822"}],"text":"Fig. 1 The abnormal activation of the Renin-Angiotensin-Aldosterone system (RAAS) pathway via the ACE-AngII-AT1R axis results in vasoconstriction (hypertension) which is treated by the usage of angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs)."}